hautnah dermatologie

, Volume 33, Issue 4, pp 42–48 | Cite as

Dermatologisches Nebenwirkungsmanagement zielgerichteter Onkologika

Schattenseiten der Targeted Therapy

Zertifizierte Fortbildung
First Online:
  • 24 Downloads

Zusammenfassung

Zielgerichtete onkologische Therapieregime haben in den letzten Jahren in vielen Indikationen zunehmend an Bedeutung gewonnen. Doch neue Wirkungen kommen meist nicht ohne neue Nebenwirkungen. Oftmals sind diese kutaner Art, wodurch dem Dermatologen eine Schlüsselrolle beim Nebenwirkungsmanagement zukommt.

This is a preview of subscription content, log in to check access.

Literatur

  1. 1.
    Hirsch FR et al. New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet 2016; 388: 1012–24CrossRefPubMedGoogle Scholar
  2. 2.
    Matter A. Bridging academic science and clinical research in the search for novel targeted anti-cancer agents. Cancer Biol Med 2015; 12: 316–27PubMedPubMedCentralGoogle Scholar
  3. 3.
    Funakoshi T et al. Infectious complications in cancer patients treated with anti-EGFR monoclonal antibodies cetuximab and panitumumab: a systematic review and meta-analysis. Cancer Treat Rev 2014; 40: 1221–9CrossRefPubMedGoogle Scholar
  4. 4.
    Gutzmer R et al. Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician. J Dermatol Ges 2011; 9: 195–202Google Scholar
  5. 5.
    Wacker B et al. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007; 13: 3913–21CrossRefPubMedGoogle Scholar
  6. 6.
    Lichtenberger BM et al. Epidermal EGFR controls cutaneus host defense and prevents inflammation. Sci Transl Med 2013; 5: 199ra111CrossRefPubMedGoogle Scholar
  7. 7.
    Gerber PA et al. Density of demodex folliculorum in patients receiving epidermal growth factor receptor inhibitors. Dermatology 2011; 222: 144–7CrossRefPubMedGoogle Scholar
  8. 8.
    Gerber PA et al. Preliminary evidence for a role of mast cells in epidermal growth factor receptor inhibitor-induced pruritus. J Am Acad Dermatol 2010; 63: 163–5CrossRefPubMedGoogle Scholar
  9. 9.
    Gerber PA et al. Mechanisms of skin aging induced by EGFR inhibitors. Support Care Cancer 2016; 24: 4241–8CrossRefPubMedGoogle Scholar
  10. 10.
    Segaert S et al. Skin toxicities of targeted therapies. Eur J Cancer 2009; 45(Suppl 1): 295–308CrossRefPubMedGoogle Scholar
  11. 11.
    Gerber PA et al. Images in clinical medicine. Erlotinib-induced hair alterations. N Engl J Med 2008; 358: 1175CrossRefPubMedGoogle Scholar
  12. 12.
    Lacouture ME et al. Clinical practice guidelines for the prevention and treatment of EGFR-inhibitor- associated dermatologic toxicities. Support Care Cancer 2011; 19: 1079–95CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Bölke E et al. Development and management of severe cutaneous side effects in head-and-neck cancer patients during concurrent radiotherapy and cetuximab. Strahlenther Onkol 2008; 184: 105–10CrossRefPubMedGoogle Scholar
  14. 14.
    Budach W et al. Severe cutaneous reaction during radiation therapy with concurrent cetuximab. N Eng J Med 2007; 357: 514–5CrossRefGoogle Scholar
  15. 15.
    Gerber PA et al. Radiation induced prevention of erlotinib-induced skin rash is transient: a new aspect toward the understanding of epidermal growth factor receptor inhibitor associated cutaneous adverse effects. J Clin Oncol 2007; 25: 4697–98 (author reply 4698–4699)CrossRefPubMedGoogle Scholar
  16. 16.
    Lacouture ME et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28: 1351–7CrossRefPubMedGoogle Scholar
  17. 17.
    Vaubel J et al. Retarded low-dose doxycycline for EGFR or MEK inhibitor-induced papulopustular rash. J Eur Acad Dermatol Venerol 2014; 28: 1685–9CrossRefGoogle Scholar
  18. 18.
    Gerber PA et al. Management of EGFR-inhibitor associated rash: a retrospective study in 49 patients. Eur J Med Res 2012; 23: 4CrossRefGoogle Scholar
  19. 19.
    Melosky B et al. Management of EGFR TKI-induced dermatologic adverse events. Curr Oncol 2015; 22: 123–32CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Gerber PA et al. The Koebner-phenomenon in epidermal growth factor receptor inhibitor associated cutaneous adverse effects. J Clin Oncol 2008; 26: 2790–2CrossRefPubMedGoogle Scholar
  21. 21.
    Jo JC et al. Topical vitamin K1 may not be effective in preventing acneiform rash during cetuximab treatment in patients with metastatic colorectal cancer. Eur J Dermatol 2013; 23: 77–82PubMedGoogle Scholar
  22. 22.
    Ocvirk J et al. A review of the treatment options for skin rash induced by EGFR-targeted therapies: evidence from randomized clinical trials and a meta-analysis. Radiol Oncol 2013; 47: 166–75CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Gerber PA et al. More on aprepitant for erlotinib-induced pruritus. N Engl J Med 2011; 364: 486–7CrossRefPubMedGoogle Scholar
  24. 24.
    Santini D et al. Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study. Lancet Oncol 2012; 13: 1020–4CrossRefPubMedGoogle Scholar
  25. 25.
    Lupu I et al. Cutaneous complications of molecular targeted therapy used in oncology. J Med Life 2016; 9: 19–25PubMedPubMedCentralGoogle Scholar
  26. 26.
    Rosenbaum SE et al. Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Support Care Cancer 2008; 16: 557–66CrossRefPubMedGoogle Scholar
  27. 27.
    Akanay-Diesel S et al. Sunitinib inuced pyoderma gangraenosum-like ulcerations. Eur J Med Res 2011; 16: 491–4CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Kong HH et al. Keratoacanthomas associated with sorafenib therapy. J Am Acad Dermatol 2007; 56: 171–2CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Degen A et al. The hand- foot-syndrome associated with medical tumor therapy — classification and management. J Dtsch Dermatol Ges 2010; 8: 652–61PubMedGoogle Scholar
  30. 30.
    Miller KK et al. Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol 2014; 71: 787–94CrossRefPubMedGoogle Scholar
  31. 31.
    Vincenzi B et al. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist 2010; 15: 85–92CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Hofheinz RD et al. Mapisal versus urea cream as prophylaxis for capecitabine- associated hand-foot syndrome: a randomized phase III trial of the AIO quality of life working group. J Clin Oncol 2015; 33: 2444–8CrossRefPubMedGoogle Scholar
  33. 33.
    Scotte F et al. Multicenter study of a frozen glove to prevent docetaxel- induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol 2005; 23: 4424–9CrossRefPubMedGoogle Scholar
  34. 34.
    Curtin JA et al. Distinct sets of genetic alterations in melanoma. N Eng J Med 2005; 353: 2135–47CrossRefGoogle Scholar
  35. 35.
    Robert C J et al. Improved overall survival in Melanoma with combined dabrafenib and trametinib. N Eng J Med 2015; 372: 30–9CrossRefGoogle Scholar
  36. 36.
    Zimmer L et al. Incidence of new primary melanoma after diagnosis of stage III and IV melanoma. J Clin Oncol 2014; 32: 816–23CrossRefPubMedGoogle Scholar
  37. 37.
    Zimmer L et al. Side effects of systemic oncological therapies in dermatology. J Dtsch Dermatol Ges 2012; 10: 475–86PubMedGoogle Scholar
  38. 38.
    Lacouture ME et al. Analysis of dermatologic events in Vemurafenib-treated patients with melanoma. Oncologist 2013; 18: 314–22CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Boussemart L et al. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol 2013; 24: 1691–7CrossRefPubMedGoogle Scholar
  40. 40.
    Dummer R et al. Ultraviolet a and photosensitivity during vemurafenib therapy. N Engl J Med 2012; 366: 480–1CrossRefPubMedGoogle Scholar
  41. 41.
    Satzger I et al. Serious skin toxicity with the combination of BRAF-inhibitors and radiotherapy. J Clin Oncol 2013; 31: e220–2CrossRefPubMedGoogle Scholar
  42. 42.
    Forschner A et al. Radiation recall dermatitis and radiation pneumonitis during treatment with vemurafenib. Melanoma Res 2014; 24: 512–6CrossRefPubMedGoogle Scholar
  43. 43.
    Golian E et al. Cutaneous Complications of targeted melanoma therapy. Curr Treat Options Oncol 2016; 17: 57CrossRefPubMedGoogle Scholar
  44. 44.
    Meurer M et al. Medikamentöse Therapie des malignen Melanoms. Hautarzt 2012; 63: 885–98CrossRefGoogle Scholar
  45. 45.
    Belum VR et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer 2016; 60: 12–25CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Beck KE et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006; 24: 2283–9CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Hodi FS et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711–23CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Lacouture ME et al. Ipilimumab in patients with cancer and the management of dermatologic adverse events. J Am Acad Dermatol 2014; 71: 161–9CrossRefPubMedGoogle Scholar
  49. 49.
    Sanlorenzo M et al. Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol 2015; 151: 1206–12CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Teulings HE et al. Vitiligo-like depigmentation in patients with stage III–IV melanoma receiving immunotherapy and ist association with survival: a systematic review and meta-analysis. J Clin Oncol 2015; 33: 773–81CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH 2017

Authors and Affiliations

  1. 1.Klinik für DermatologieUniversitätsklinikum DüsseldorfDüsseldorfDeutschland

Personalised recommendations